SWShengcai Wang

Shengcai Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shengcai Wang has a total of 135 co-authors. Here are the top co-authors by number of shared publications:

  • Xin Ni

    Department of Otolaryngology, Head and Neck Surgery, National Center for Children’s Health (Beijing), Beijing Children’s Hospital, Capital Medical University, No. 56 Nanlishi Road, Xicheng District, Beijing 100045, China

    66 shared publications
  • Nian Sun

    Department of Otolaryngology, Head and Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    49 shared publications
  • Chenghao Chen

    Beijing Children’s Hospital, Capital Medical University

    46 shared publications
  • Fang Jin

    Department of Clinical Laboratory Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    46 shared publications
  • Haiyan Cheng

    Department of Oncology Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, PR China

    46 shared publications
  • Huanmin Wang

    Department of Surgical Oncology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China

    46 shared publications

Latest Publications

  • Open Access

    The clinicopathologic and molecular profile of second primary thyroid cancer in pediatric cancer survivors

    by Liu Yuwei, Yang Ailei, Li Yanzhen, Zhang Xuexi, Sun Nian, Liu Qiaoyin, Liu Zhiyong, Tan Junlong, Pang Wei, Ni Xin, et al.

    Objective: To characterize the clinicopathological and molecular profiles, treatment, and outcomes of second primary thyroid cancer (SPTC) in childhood cancer survivors to inform risk-stratified surveillance and management. Methods: This retrospective case series enrolled patients (aged ≤18 years at thyroid cancer diagnosis) with SPTC at Beijing Children's Hospital (2016-2024). Inclusion required a history of childhood malignancy treated with radiotherapy and/or chemotherapy. Data on demographics, primary cancer, SPTC characteristics, treatment, outcomes and molecular alterations were collected. Results: Twelve survivors with SPTC were included. The median age at primary cancer diagnosis was 4.3 years, with neuroblastoma/ganglioneuroblastoma (33.3%) and lymphoma (25.0%) being the most common. The median latency to SPTC diagnosis was 5.4 years. Most SPTCs (75.0%) were detected incidentally on surveillance imaging. Despite 75.0% presenting as T1-stage, the rate of lymph node metastasis (LNM) was notably high (75.0%). Molecular testing in six patients revealed diverse drivers, including a germline TP53 mutation (Li-Fraumeni syndrome), NTRK3 , ALK , and RET fusions, and a BRAF V600E mutation. At a median follow-up, half of patients were disease-free, 25.0% experienced recurrence, and one patient died. Conclusion: SPTC in childhood cancer survivors may represent a distinct entity characterized by early-stage presentation yet aggressive nodal spread and diverse genomic landscape. These findings highlight the potential value of comprehensive molecular testing for all such patients to identify occult cancer predisposition syndromes and actionable oncogenic alterations, facilitating personalized precision medicine. However, given the small sample size and incomplete molecular data, these findings require validation in larger prospective cohorts.

  • Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing

    by Bo Liu, Xiao-Lin Xu, Jia-Lu Wang, Jia Li, Yu-Xin Wu, Xue-Xi Zhang, Qiao-Yin Liu, Yi-Ming Zhao, Peng Guo, Rui-Qi Zhang, et al.

  • Multidimensional outcomes of initial treatment strategies for pediatric head and neck lymphatic malformations

    by Jie Li, Yiran Meng, Jialu Wang, Qiaoyin Liu, Xuexi Zhang, Lin Mei, Zhiyong Liu, Nian Sun, Junlong Tan, Yanzhen Li, et al.

    Purpose To compare real-world initial treatment strategies for pediatric head and neck lymphatic malformations using a multidimensional outcome framework that distinguishes complete radiological response, objective lesion response, progression control, and treatment burden, and to examine how lesion complexity influences treatment selection and outcomes. Methods We conducted a retrospective cohort study of pediatric patients with head and neck lymphatic malformations treated at a tertiary referral center between January 2016 and December 2025. Patients were categorized into surgery alone, interventional therapy alone, medical therapy alone, or combined therapy according to the initial treatment strategy. Radiological outcomes were classified as complete response, partial response, stable disease, or progression/recurrence. Primary outcomes included complete response, objective response rate, progression/recurrence, and progression-free survival. Lesion complexity was classified using an exploratory, literature-informed framework based on De Serres stage, cystic subtype, number of involved anatomical regions, and critical structure involvement. Multivariable logistic regression, generalized propensity score-based overlap weighting, propensity score matching, event-density analysis, and follow-up sensitivity analyses were used to address confounding by indication and unequal follow-up. Results Among 210 patients, 40 received surgery alone, 110 interventional therapy alone, 23 medical therapy alone, and 37 combined therapy. Surgery alone achieved the highest complete response rate (75.0%). Interventional therapy alone showed the highest objective response rate (87.3%), highest disease control rate (95.5%), lowest progression/recurrence rate (4.5%), and lowest additional-treatment rate (4.5%). Medical therapy alone had the highest progression/recurrence rate (39.1%), a pattern that may at least partly reflect the selection of systemic therapy for more complex disease, although a contribution from limited treatment effect in this heterogeneous group cannot be excluded. High-complexity lesions were less likely to achieve complete response and had numerically higher progression/recurrence. The main outcome patterns remained directionally consistent after multivariable adjustment, overlap weighting, propensity score-matched sensitivity analysis, and follow-up sensitivity analyses. Conclusion Initial treatment strategies for pediatric head and neck lymphatic malformations demonstrated distinct outcome profiles rather than a simple hierarchy of effectiveness. Surgery alone was most strongly associated with complete radiological response, whereas interventional therapy alone showed a favorable objective-response and progression-control profile. A multidimensional framework integrating eradication, objective response, lesion complexity, treatment burden, and progression control may better support individualized treatment selection.

  • Open Access

    A single-center retrospective study of a decade-long experience in managing pediatric lymphatic malformation

    by Yiran Meng, Jialu Wang, Yanni Wang, Wenyuan Shi, Jie Li, Xuexi Zhang, Ge Zhang, Qiaoyin Liu, Zhiyong Liu, Yanzhen Li, et al.

    Lymphatic malformations (LMs) are rare pediatric conditions that present variable symptoms depending on lesion size and anatomical location, necessitating

  • Open Access

    Supplementary Figure 11 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 11 Low-dose doxorubicin affects the expression of CD112 and CD155 in NB cells. (A) The apoptosis of SH-SY5Y and SK-N-BE2 cells treated with low-dose doxorubicin (0.1 μM) is detected by FACS (left) and AV+ proportion is labeled in the representative FACS histograms. (B-F) CD112 and CD155 expression in SH-SY5Y and SK-N-BE2 cells or primary NB tumor cells treated with low-dose doxorubicin (0.1 μM) are detected by FACS and Western blot. MFI is labeled in the representative FACS histograms. (G) and (H) The cytotoxicity assays are performed to detected γδT-cell cytotoxicity against SH-SY5Y and SK-N-BE2 cells pretreated with 0.1 μM doxorubicin. The results are expressed as the means ± SEMs from at least three independent experiments. Significant differences between groups are represented by * p < 0.05 and *** p < 0.001.

  • Open Access

    Supplementary Figure 10 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 10 Identification of Tet-on system, ROC curves and survival curves of different groups for NB tumor. (A) and (B) The variation of CD112 and CD155 expression in SK-N-BE2 cells treated with different concentration of doxycycline (0, 2 nM, 20 nM, 200 nM, 2 μM, 20 μM) is detected by qPCR and Western blot. (C) ROC curves are generated for CD112, CD155, and CD112/CD155 ratio to predict NB patient death, tumor risk or MYCN amplification. The results are expressed as the means ± SEMs from at least three independent experiments. Significant differences between groups are represented by ns no significance, * p < 0.05, ** p < 0.01 and *** p < 0.001.

  • Open Access

    Supplementary Figure 6 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 6 The cell-cycle scores and expression of functional genes in tumor cells and γδT cells in spatial transcriptome analysis and scRNA sequencing analysis. (A) Cell-cycle score analysis of tumor cells in spatial transcriptome analysis. (B) Spatial distribution and expression of proliferating markers. (C) Cell-cycle score analysis of tumor cells in scRNA sequencing analysis. (D) Violin plots showing the expression levels of neuroblastoma related genes in tumor cells in scRNA sequencing analysis. (E) and (F) Cell-cycle score and GSVA score analysis of γδT cells in scRNA sequencing analysis. (G) Violin plots showing the expression levels of DNAM-1, TIGIT, CD96, PD-1, TIM-3, IFN-γ, granzyme B and perforin in γδT cells in scRNA sequencing analysis.

  • Open Access

    Supplementary Figure 12 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 12 The effects of CD112 on γδT-cell-cytotoxicity against neuroblastoma, and on proliferation and migration of NB cells. (A-D) rhCD112 is used to treat γδT cells for 24 h. TIGIT, CD96 and CD112R are detected by FACS (left) or Western blot and MFI is labeled in the representative FACS histograms (right). (E) γδT-cell numbers are counted and statistically analyzed during in vitro culture in presence of rhCD112. (F) The CFSE proliferation assays are performed during in vitro culture in presence of rhCD112. γδT cells are detected by FACS (right) and statistically analyzed (left). MFI is labeled in the representative FACS histograms. (G) γδT cells are pre-treated with rhCD112 for 24 h and subjected to calcium flux detection by Fluo-4 AM labeling and low-concentration PMA and ionomycin stimulation. The calcium flux results are used to benchmark the levels of activation. The results are recorded and illustrated by FACS (right) and statistically analyzed (left). (H) The phosphorylation of Akt and ERK1/2 in γδT cells is detected by Western blot after treatment using rhCD112 with or without α-DNAM-1 for 24 h. (I) and (J) The cytotoxicity assays are performed with γδT cells pre-treated with rhCD112 for 24 h and NB cell lines. (K) and (L) The cytotoxicity assays are performed to detected γδT-cell cytotoxicity against SH-SY5Y and CHLA-255 cells in presence of α-CD112. (M-O) CCK-8, Transwell and wound-healing sassays are performed using CHLA-255-NC and CHLA-255-shCD112 cells. Representative images of CHLA-255 cell migration obtained from the Transwell (magnification × 100) and wound-healing (magnification × 100) assays are shown (right). The cell numbers obtained from the Transwell assays are counted, and the relative migration rate obtained from the wound-healing assays is calculated by dividing the change in the distance between the scratch edges by the initial distance (left). (P) CD112 is overexpressed in IMR-32 cells transiently by transfecting constructed CD112 vector and CD112 expression is detected by qPCR, FACS and Western blot. MFI is labeled in the representative FACS histograms. (Q) DNAM-1 reduction is detected by FACS after 24 h co-culture with IMR-32-vector or IMR-32-CD112 cells (left) and MFI is labeled in the representative FACS histograms (right). (R) The phosphorylation of Akt and ERK1/2 in γδT cells is detected by Western blot after CHLA-255-NC and CHLA-255-shCD112 stimulation. (S) The cytotoxicity assays are performed to detected γδT-cell cytotoxicity against IMR-32-vector and IMR-32-CD112 cells. The results are expressed as the means ± SEMs from at least three independent experiments. Significant differences between groups are represented by ns no significance, * p < 0.05, ** p < 0.01 and *** p < 0.001.

  • Open Access

    Supplementary Figure 1 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 1 Identified major cell types, cell proportion analysis and CD112 and CD155 expression in NB tumor scRNA-seq analysis. (A) Violin plots showing the number of features, RNA counts and percent mitochondrial transcripts following quality control. (B) Violin plots showing the average expression of the genes for annotating the major cell types identified in NB tumors. (C) UMAP plots showing the distribution of cell types for each sample. (D) Bar plots showing the proportions of cell types for each sample. (E) UMAP plots showing the expression levels of CD112 and CD155.

  • Open Access

    Supplementary Figure 13 from Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor–Ligand Interactions That Instructs Intratumoral γδT-cell Activity

    by Xiaolin Wang, Hui Wang, Zhengjing Lu, Xiangjun Liu, Wenjia Chai, Wei Wang, Jun Feng, Shen Yang, Wei Yang, Haiyan Cheng, et al.

    Supplementary Figure 13 The effects of CD155 on γδT-cell-cytotoxicity against neuroblastoma, and on proliferation and migration of NB cells. (A) and (B) α-TIGIT is used in the rhCD155 treatment of γδT cells. DNAM-1 is detected by FACS and Western blot. (C-F) rhCD155 is used to treat γδT cells for 24 h. TIGIT, CD96 and CD112R are detected by FACS (left) or Western blot and MFI is labeled in the representative FACS histograms (right). (G) γδT-cell numbers are counted and statistically analyzed during in vitro culture in presence of rhCD155. (H) The CFSE proliferation assays are performed during in vitro culture in presence of rhCD155. γδT cells are detected by FACS (right) and statistically analyzed (left). MFI is labeled in the representative FACS histograms. (I) γδT cells are pre-treated with rhCD155 for 24 h and subjected to calcium flux detection by Fluo-4 AM labeling and low-concentration PMA and ionomycin stimulation. The calcium flux results are used to benchmark the levels of activation. The results are recorded and illustrated by FACS (right) and statistically analyzed (left). (J) The phosphorylation of Akt and ERK1/2 in γδT cells is detected by Western blot after treatment using rhCD155 for 24 h. (K) and (L) The cytotoxicity assays are performed with γδT cells pre-treated with rhCD155 or α-TIGIT for 24 h and NB cell lines. (M) and (N) The cytotoxicity assays are performed to detected γδT-cell cytotoxicity against SH-SY5Y and CHLA-255 cells in presence of α-CD155. (O-Q) IFN-γ, perforin and granzyme B expression are detected by FACS upon PMA and ionomycin stimulation after rhCD155 pre-treatment (left) and MFI is labeled in the representative FACS histograms (right). (R-T) CCK-8, Transwell and wound-healing sassays are performed using SK-N-BE2-NC and SK-N-BE2-KoCD155 cells. Representative images of SK-N-BE2 cell migration obtained from the Transwell (magnification × 100) and wound-healing (magnification × 100) assays are shown (right). The cell numbers obtained from the Transwell assays are counted, and the relative migration rate obtained from the wound-healing assays is calculated by dividing the change in the distance between the scratch edges by the initial distance (left). (U) The phosphorylation of Akt and ERK1/2 in γδT cells is detected by Western blot after SK-N-BE2-NC and SK-N-BE2-KoCD155 stimulation. (V) TIGIT is detected by FACS after 24 h co-culture with SK-N-BE2-NC and SK-N-BE2-KoCD155 cells (left) and MFI is labeled in the representative FACS histograms (right). The results are expressed as the means ± SEMs from at least three independent experiments. Significant differences between groups are represented by ns no significance, * p < 0.05, ** p < 0.01 and *** p < 0.001.